Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance, which is influenced by immune composition, metabolic reprogramming, and innate immune sensing pathways [2] - The analysis integrated data from over 7,000 patients, highlighting the context-dependent nature of these biomarkers [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The publication reflects the foundation's commitment to bridging scientific inquiry with real-world research experience [3][5] Group 3: Author Insights - Dr. Drashya Shah, an intern supported by the Brush and Key Foundation, emphasized the value of mentorship in enhancing research quality and personal confidence [4] - Dr. Vuong Trieu noted the intersection of bioinformatics, translational oncology, and mentorship in generating scientific insights [4] - Dr. Wen-Han Chang highlighted the importance of considering tumor context when interpreting biomarkers [4] Group 4: Company Background - Oncotelic Therapeutics, originally founded as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is involved in developing treatments for various cancers and conditions, including Parkinson's Disease and erectile dysfunction [6][7][8]